Detection of anti-MtsA antibodies in sera from Kunming mice that

Detection of anti-MtsA antibodies in sera from Kunming mice that were experimentally infected with S. iniae HD-1 To detect the presence of specific anti-MtsA antibodies in the sera from Kunming mice, 10 male Kunming mice (20 ± 2 g) were purchased from Guangdong Laboratory Animals Research Center, and approval from the Animal Ethics Committee

of Life Sciences Institute was obtained prior to using the animals for research. The experiments were performed as stipulated by the China State Science and Technology Commission [47]. Mice were acclimatized at the SPF animal center and fed twice daily for 2 weeks in the laboratory Sorafenib cost of the Life Science Institute prior to use. Each mouse was injected with 100 μl of 6.2 × 108 CFU ml-1 S. iniae HD-1 cells, and the infected sera were collected 10 days post infection. The infected sera and purified MtsA were used in dot-blot and western-blot assays. The sera from 10 Kunming mice injected with PBS were used as the negative control. Statistical analysis The nucleotide and deduced amino acid homology analysis of mtsABC was carried out by ClustalX 1.83 and NCBI BLAST http://​blast.​ncbi.​nlm.​nih.​gov/​Blast.​cgi.

The presumed signal sequence was predicted by the signalP 3.0 Server http://​www.​cbs.​dtu.​dk/​services/​SignalP/​. The theoretical pI/MW was analyzed by the ExPASy Compute pI/MW tool http://​www.​expasy.​org/​tools/​pi_​tool.​html. Peptide 17 molecular weight The main domains of mtsABC were detected by the SMART software http://​smart.​embl-heidelberg.​de/​. The amino acid sequences Olopatadine were aligned using the SECentral Align Multi 4 program. To determine

whether mtsABC is a Lipoprotein, its sequence was assessed by the ScanProsite analysis software http://​www.​expasy.​ch/​tools/​scanprosite/​. All statistical analyses were performed using the SPSS 16.0 software (SPSS Inc., USA). Acknowledgements Project support was provided in parts by grants from Key Projects in the National Science & Technology Pillar Program in the Eleventh Five-year Plan Period (2007BAD29B05) to Dr. An-Xing Li. Project support was provided in parts by grants from Chongqing Engineering Technology Research Centre of Veterinary Drug (CSTC, 2009CB1010) to Dr. Lili Zou. We thank Prof. Shaoping Weng and Drs. Lichao Huang, Xiangyun Wu, Yangsheng Wu, Jianfeng Yuan, and Suming Zhou for their helpful technical advice. We also thank Dr. Shenquan Liao for providing plasmid pet-32a-c (+) used in this study, and the professional copyediting service from the International Science Editing. Electronic supplementary material Additional file 1: Tables 1-7. Microsoft word file containing Tables 1-7 as individual tab-accessible tables within a single file (Volasertib in vitro Supplemental Tables 1-7). (DOC 128 KB) Additional file 2: Figures 1-4. Microsoft word file containing Figures 1, 2, 3, 4 as individual tab-accessible figures within a single file (Supplemental Figures 1-4). (DOC 358 KB) References 1.

Comments are closed.